Update shared on05 Sep 2025
With both future P/E and consensus revenue growth forecasts essentially unchanged, there has been no meaningful revision to H. Lundbeck's analyst price target, which remains at DKK48.18.
What's in the News
- New data on bexicaserin, an investigational treatment for seizures in DEEs, to be presented; the drug is in global Phase 3 trials with FDA Breakthrough Therapy designation and has shown durable seizure reduction.
- Lundbeck raised its 2025 full-year revenue growth guidance to 11%-13% from 8%-11% previously.
- FDA advisory committee voted against the efficacy of REXULTI (brexpiprazole) plus sertraline for PTSD, questioning its effectiveness for this indication.
- SUNRISE trial met all primary and secondary endpoints for eptinezumab in chronic migraine, showing significant reduction in migraine frequency and burden; discussions with regulators in Asia have commenced.
- Multiple studies and post-hoc analyses reinforce VYEPTI's (eptinezumab-jjmr) preventive efficacy, retention rates, and positive patient experience in migraine, with comprehensive presentations at major neurology and headache conferences.
Valuation Changes
Summary of Valuation Changes for H. Lundbeck
- The Consensus Analyst Price Target remained effectively unchanged, at DKK48.18.
- The Future P/E for H. Lundbeck remained effectively unchanged, moving only marginally from 12.10x to 12.16x.
- The Consensus Revenue Growth forecasts for H. Lundbeck remained effectively unchanged, at 3.5% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.